Fibromyalgia-Pipeline Review, H2 2015

Fibromyalgia-Pipeline Review, H2 2015

  • Products Id :- GMDHC6997IDB
  • |
  • Pages: 66
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fibromyalgia-Pipeline Review, H2 2015


Global Markets Direct's, 'Fibromyalgia-Pipeline Review, H2 2015', provides an overview of the Fibromyalgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Fibromyalgia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fibromyalgia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fibromyalgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fibromyalgia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fibromyalgia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fibromyalgia Overview 7

Therapeutics Development 8

Pipeline Products for Fibromyalgia-Overview 8

Pipeline Products for Fibromyalgia-Comparative Analysis 9

Fibromyalgia-Therapeutics under Development by Companies 10

Fibromyalgia-Therapeutics under Investigation by Universities/Institutes 11

Fibromyalgia-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Fibromyalgia-Products under Development by Companies 15

Fibromyalgia-Products under Investigation by Universities/Institutes 16

Fibromyalgia-Companies Involved in Therapeutics Development 17

Daiichi Sankyo Company, Limited 17

Intellipharmaceutics International Inc. 18

Merck & Co., Inc. 19

SWITCH Biotech LLC 20

Tonix Pharmaceuticals Holding Corp. 21

Zynerba Pharmaceuticals, Inc. 22

Fibromyalgia-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

mirogabalin besylate-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

mirtazapine ODT-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

naltrexone hydrochloride-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

pregabalin XR-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules for Fibromyalgia-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

SWT-06101-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

TD-9855-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

TNX-102-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ZYN-001-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Fibromyalgia-Recent Pipeline Updates 44

Fibromyalgia-Dormant Projects 53

Fibromyalgia-Discontinued Products 56

Fibromyalgia-Product Development Milestones 57

Featured News & Press Releases 57

Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg 57

Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR 57

May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR 59

May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR 59

May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia 60

Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate 60

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 61

Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia 62

Sep 29, 2014: Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia 62

May 12, 2014: Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

Number of Products under Development for Fibromyalgia, H2 2015 8

Number of Products under Development for Fibromyalgia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Products under Investigation by Universities/Institutes, H2 2015 16

Fibromyalgia-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 17

Fibromyalgia-Pipeline by Intellipharmaceutics International Inc., H2 2015 18

Fibromyalgia-Pipeline by Merck & Co., Inc., H2 2015 19

Fibromyalgia-Pipeline by SWITCH Biotech LLC, H2 2015 20

Fibromyalgia-Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015 21

Fibromyalgia-Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 22

Assessment by Monotherapy Products, H2 2015 23

Number of Products by Stage and Target, H2 2015 25

Number of Products by Stage and Mechanism of Action, H2 2015 27

Number of Products by Stage and Route of Administration, H2 2015 29

Number of Products by Stage and Molecule Type, H2 2015 31

Fibromyalgia Therapeutics-Recent Pipeline Updates, H2 2015 44

Fibromyalgia-Dormant Projects, H2 2015 53

Fibromyalgia-Dormant Projects (Contd..1), H2 2015 54

Fibromyalgia-Dormant Projects (Contd..2), H2 2015 55

Fibromyalgia-Discontinued Products, H2 2015 56

List of Figures

Number of Products under Development for Fibromyalgia, H2 2015 8

Number of Products under Development for Fibromyalgia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Products, H2 2015 14

Assessment by Monotherapy Products, H2 2015 23

Number of Products by Top 10 Targets, H2 2015 24

Number of Products by Stage and Top 10 Targets, H2 2015 24

Number of Products by Top 10 Mechanism of Actions, H2 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 26

Number of Products by Top 10 Routes of Administration, H2 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 28

Number of Products by Top 10 Molecule Types, H2 2015 30

Number of Products by Stage and Top 10 Molecule Types, H2 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Daiichi Sankyo Company, Limited

Intellipharmaceutics International Inc.

Merck & Co., Inc.


Tonix Pharmaceuticals Holding Corp.

Zynerba Pharmaceuticals, Inc.

Fibromyalgia Therapeutic Products under Development, Key Players in Fibromyalgia Therapeutics, Fibromyalgia Pipeline Overview, Fibromyalgia Pipeline, Fibromyalgia Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]